{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:29:17Z","timestamp":1791822557096,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ratchadapisek Somphot Matching Fund, Faculty of Medicine, Chulalongkorn University","award":["RA-MF-01\/69"],"award-info":[{"award-number":["RA-MF-01\/69"]}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"crossref","award":["N42A680423"],"award-info":[{"award-number":["N42A680423"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16207-8","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:24:45Z","timestamp":1780032285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Atezolizumab versus pembrolizumab in the treatment of advanced triple-negative breast cancer: a Bayesian network meta-analysis of ITT and PD-L1 positive populations"],"prefix":"10.1186","volume":"26","author":[{"given":"I Gede Wikania Wira","family":"Wiguna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I Gede Krisna Arim","family":"Sadeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christo Timothy","family":"Mamangdean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngakan Putu Krishna","family":"Mahayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparada","family":"Khanaruksombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Soe","family":"Thu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putu Mirah Wahyu Subagia","family":"Putri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadek Meryndha Kumala","family":"Tungga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agung Brahmanthya Nadine","family":"Kepakisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komang Indra Parama","family":"Arta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raditya Putra","family":"Pratama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"16207_CR1","doi-asserted-by":"publisher","first-page":"1405491","DOI":"10.3389\/fonc.2024.1405491","volume":"14","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14:1405491.","journal-title":"Front Oncol"},{"key":"16207_CR2","doi-asserted-by":"publisher","first-page":"836417","DOI":"10.3389\/fmolb.2022.836417","volume":"9","author":"NM Almansour","year":"2022","unstructured":"Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022;9:836417.","journal-title":"Front Mol Biosci"},{"key":"16207_CR3","doi-asserted-by":"publisher","first-page":"1465511","DOI":"10.3389\/fonc.2025.1465511","volume":"15","author":"M Darida","year":"2025","unstructured":"Darida M, Rubovszky G, Kiss Z, Sz\u00e9kely B, Madaras B, Horv\u00e1th Z, et al. Improvement in breast cancer survival across molecular subtypes in Hungary between 2011 and 2020: a nationwide, retrospective study. Front Oncol. 2025;15:1465511.","journal-title":"Front Oncol"},{"key":"16207_CR4","doi-asserted-by":"publisher","unstructured":"KesireddyM, Elsayed L, Shostrom VK, Agarwal P, Asif S, Yellala A et al. Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers (Basel). 2024;16(10):1791. https:\/\/doi.org\/10.3390\/cancers16101791.","DOI":"10.3390\/cancers16101791"},{"key":"16207_CR5","first-page":"265","volume":"17","author":"H Jie","year":"2025","unstructured":"Jie H, Ma W, Huang C. Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review. Breast cancer (Dove Med Press. 2025;17:265\u201374.","journal-title":"Breast cancer (Dove Med Press"},{"key":"16207_CR6","doi-asserted-by":"publisher","unstructured":"LiL, Zhang F, Liu Z, Fan Z. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. Cancers (Basel). 2023;15(1):321. https:\/\/doi.org\/10.3390\/cancers15010321.","DOI":"10.3390\/cancers15010321"},{"issue":"3","key":"16207_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387(3):217\u201326.","journal-title":"N Engl J Med"},{"issue":"22","key":"16207_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"16207_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Gligorov J, Andr\u00e9 F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(8):994\u20131004.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"16207_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","volume":"35","author":"R Dent","year":"2024","unstructured":"Dent R, Andr\u00e9 F, Gon\u00e7alves A, Martin M, Schmid P, Sch\u00fctz F, et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2024;35(7):630\u201342.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"16207_CR11","doi-asserted-by":"publisher","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. Available from: https:\/\/doi.org\/10.1136\/bmj.n160","DOI":"10.1136\/bmj.n160"},{"issue":"8","key":"16207_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH, Di\u00e9ras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(8):983\u201393.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"16207_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44\u201359.","journal-title":"Lancet Oncol"},{"key":"16207_CR14","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In. 2008. Available from: https:\/\/api.semanticscholar.org\/CorpusID:76535584","DOI":"10.1002\/9780470712184.ch8"},{"key":"16207_CR15","doi-asserted-by":"publisher","unstructured":"Bezerra CT, Grande AJ, Galv\u00e3o VK, Santos DHM, Dos, Atallah \u00c1N, Silva V. Assessment of the strength of recommendation and quality of evidence: GRADE checklist. A descriptive study. Sao Paulo Med J. 2022;140(6):829\u201336. Available from: https:\/\/doi.org\/10.1590\/1516-3180.2022.0043.R1.07042022","DOI":"10.1590\/1516-3180.2022.0043.R1.07042022"},{"key":"16207_CR16","doi-asserted-by":"publisher","unstructured":"MbuagbawL, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6(1):79. https:\/\/doi.org\/10.1186\/s13643-017-0473-z.","DOI":"10.1186\/s13643-017-0473-z"},{"issue":"5","key":"16207_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.annonc.2020.02.003","volume":"31","author":"S Adams","year":"2020","unstructured":"Adams S, Di\u00e9ras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(5):582\u20139.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10265","key":"16207_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328.","journal-title":"Lancet"},{"issue":"9","key":"16207_CR19","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.1002\/cam4.5757","volume":"12","author":"M Hattori","year":"2023","unstructured":"Hattori M, Masuda N, Takano T, Tsugawa K, Inoue K, Matsumoto K, et al. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355. Cancer Med. 2023;12(9):10280\u201393.","journal-title":"Cancer Med"},{"issue":"5","key":"16207_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol Off J Eur Soc Med Oncol. 2022;33(5):534\u201343.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"16207_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41523-024-00679-7","volume":"10","author":"SA Im","year":"2024","unstructured":"Im SA, Cortes J, Cescon DW, Yusof MM, Iwata H, Masuda N, et al. Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. NPJ breast cancer. 2024;10(1):79.","journal-title":"NPJ breast cancer"},{"issue":"10","key":"16207_CR22","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1158\/1078-0432.CCR-19-3545","volume":"26","author":"P Narayan","year":"2020","unstructured":"Narayan P, Wahby S, Gao JJ, Amiri-Kordestani L, Ibrahim A, Bloomquist E, et al. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1. Clin cancer Res Off J Am Assoc Cancer Res. 2020;26(10):2284\u20139.","journal-title":"Clin cancer Res Off J Am Assoc Cancer Res"},{"key":"16207_CR23","doi-asserted-by":"publisher","first-page":"175883592513279","DOI":"10.1177\/17588359251327992","volume":"17","author":"P Schmid","year":"2025","unstructured":"Schmid P, Oliveira M, O\u2019Shaughnessy J, Cristofanilli M, Graff SL, Im SA, et al. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2025;17:17588359251327992\u201317588359251327992.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"16207_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499\u2013511.","journal-title":"Lancet Oncol"},{"issue":"9","key":"16207_CR25","doi-asserted-by":"publisher","first-page":"e1624128","DOI":"10.1080\/2162402X.2019.1624128","volume":"8","author":"N Mohan","year":"2019","unstructured":"Mohan N, Hosain S, Zhao J, Shen Y, Luo X, Jiang J, et al. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1(+) triple negative breast cancer cells. Oncoimmunology. 2019;8(9):e1624128.","journal-title":"Oncoimmunology"},{"issue":"1","key":"16207_CR26","doi-asserted-by":"publisher","first-page":"13427","DOI":"10.1038\/s41598-023-40569-9","volume":"13","author":"A de Moura","year":"2023","unstructured":"de Moura A, Vuagnat P, Renouf B, Pierga JY, Loirat D, Vaflard P, et al. Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program. Sci Rep. 2023;13(1):13427.","journal-title":"Sci Rep"},{"key":"16207_CR27","doi-asserted-by":"publisher","first-page":"1153990","DOI":"10.3389\/fimmu.2023.1153990","volume":"14","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Li S, Tang H, Meng X, Zheng Q. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Front Immunol. 2023;14:1153990.","journal-title":"Front Immunol"},{"issue":"1","key":"16207_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41523-023-00579-2","volume":"9","author":"A Fabi","year":"2023","unstructured":"Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, et al. Real-world ANASTASE study of atezolizumab\u2009+\u2009nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. NPJ breast cancer. 2023;9(1):73.","journal-title":"NPJ breast cancer"},{"issue":"38","key":"16207_CR29","doi-asserted-by":"publisher","first-page":"63290","DOI":"10.18632\/oncotarget.18796","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Sun J, Rong R, Li L, Shang W, Song D, et al. HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape. Oncotarget. 2017;8(38):63290\u20138.","journal-title":"Oncotarget"},{"key":"16207_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.12703\/r\/10-4","volume":"10","author":"S Ritchie","year":"2021","unstructured":"Ritchie S, Reed DA, Pereira BA, Timpson P. The cancer cell secretome drives cooperative manipulation of the tumour microenvironment to accelerate tumourigenesis. Fac Rev. 2021;10:4.","journal-title":"Fac Rev"},{"key":"16207_CR31","doi-asserted-by":"crossref","unstructured":"Mukai H, Miki N, Yamada H, Goto H, Kawakami T, Suzuki A et al. Pannexin1 channel-dependent secretome from apoptotic tumor cells shapes immune-escape microenvironment. Biochem Biophys Res Commun. 2022;628:116\u201322. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006291X22011998","DOI":"10.1016\/j.bbrc.2022.08.062"},{"issue":"5","key":"16207_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41419-024-06726-2","volume":"15","author":"K Wu","year":"2024","unstructured":"Wu K, Zhang G, Shen C, Zhu L, Yu C, Sartorius K, et al. Role of T cells in liver metastasis. Cell Death Dis. 2024;15(5):341.","journal-title":"Cell Death Dis"},{"issue":"5","key":"16207_CR33","first-page":"1845","volume":"11","author":"M Yang","year":"2021","unstructured":"Yang M, Zhang C. The role of liver sinusoidal endothelial cells in cancer liver metastasis. Am J Cancer Res. 2021;11(5):1845\u201360.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"16207_CR34","doi-asserted-by":"publisher","first-page":"e70004","DOI":"10.1111\/1759-7714.70004","volume":"16","author":"YJ Cha","year":"2025","unstructured":"Cha YJ, Kim HM, Koo JS. Inherent PD-L1 22C3 Expression in Alveolar Macrophages Impacts the Combined Positive Score Status in Breast Cancer With Pulmonary Metastasis. Thorac cancer. 2025;16(5):e70004.","journal-title":"Thorac cancer"},{"issue":"12","key":"16207_CR35","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/2159-8290.CD-23-0299","volume":"13","author":"I Yofe","year":"2023","unstructured":"Yofe I, Shami T, Cohen N, Landsberger T, Sheban F, Stoler-Barak L, et al. Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary. Cancer Discov. 2023;13(12):2610\u201331.","journal-title":"Cancer Discov"},{"issue":"1","key":"16207_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00774-020-01182-2","volume":"39","author":"K Okamoto","year":"2021","unstructured":"Okamoto K. Role of RANKL in cancer development and metastasis. J Bone Min Metab. 2021;39(1):71\u201381.","journal-title":"J Bone Min Metab"},{"key":"16207_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fcell.2020.00076","volume":"8","author":"X Wu","year":"2020","unstructured":"Wu X, Li F, Dang L, Liang C, Lu A, Zhang G. RANKL\/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies. Front cell Dev Biol. 2020;8:76.","journal-title":"Front cell Dev Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16207-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:24:32Z","timestamp":1785756272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16207-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16207"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16207-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8627114\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this study as it is a meta-analysis of previously published, publicly available data and does not involve the collection of primary data from human participants. However, several amendments to the PROSPERO protocol registration have been made, following the necessary changes and adjustments to the protocol, such as the addition of RMST analysis, changes to the title, the addition of GRADE assessment analysis and other adjustments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"928"}}